tiprankstipranks
Advertisement
Advertisement

CTXR Stock Latest News

Citius Expands LYMPHIR Access with First European Shipment
Company AnnouncementsCitius Expands LYMPHIR Access with First European Shipment
5d ago
8K
CTXR
Citius Oncology announces initial shipment of LYMPHIR to Europe
PremiumThe Fly
Citius Oncology announces initial shipment of LYMPHIR to Europe
6d ago
CTOR
CTXR
Citius Pharmaceuticals Raises $5 Million in Securities Offering
PremiumCompany Announcements
Citius Pharmaceuticals Raises $5 Million in Securities Offering
10d ago
8K
CTXR
Citius Pharmaceuticals announces $5M registered direct offering priced ATM
PremiumThe Fly
Citius Pharmaceuticals announces $5M registered direct offering priced ATM
11d ago
CTXR
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
PremiumCompany Announcements
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
28d ago
8K
CTXR
Citius Oncology advances LYMPHIR launch and global expansion
PremiumCompany AnnouncementsCitius Oncology advances LYMPHIR launch and global expansion
1M ago
8K
CTXR
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data
Premium
Company Announcements
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data
2M ago
8K
CTXR
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data
Premium
Company Announcements
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data
2M ago
8K
CTXR
Citius Pharmaceuticals receives $3.8M through NJEDA program
PremiumThe Fly
Citius Pharmaceuticals receives $3.8M through NJEDA program
2M ago
CTXR
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk
PremiumCompany Announcements
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk
3M ago
8K
CTXR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
PremiumThe Fly
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
3M ago
CTOR
CTXR
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
PremiumThe Fly
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
3M ago
CTOR
CTXR
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
PremiumThe FlyCitius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
3M ago
CTOR
CTXR
Is CTXR a Buy, Before Earnings?
Premium
Pre-Earnings
Is CTXR a Buy, Before Earnings?
3M ago
CTXR
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
Premium
The Fly
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
5M ago
CTOR
CTXR
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma
PremiumCompany Announcements
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma
5M ago
8K
CTXR
Citius Oncology to advance launch of Lymphir with Verix AI integration
PremiumThe Fly
Citius Oncology to advance launch of Lymphir with Verix AI integration
5M ago
CTOR
CTXR
Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans
PremiumCompany Announcements
Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans
6M ago
8K
CTXR
Citius Pharmaceuticals Secures $6M in Stock Offering
PremiumCompany Announcements
Citius Pharmaceuticals Secures $6M in Stock Offering
7M ago
8K
CTXR
Citius Pharmaceuticals announces $6M registered direct offering priced ATM
PremiumThe FlyCitius Pharmaceuticals announces $6M registered direct offering priced ATM
7M ago
CTXR
Citius Oncology announces distribution agreement with McKesson
Premium
The Fly
Citius Oncology announces distribution agreement with McKesson
7M ago
MCK
CTOR
Citius Oncology signs exclusive commercialization agreement with EVERSANA
Premium
The Fly
Citius Oncology signs exclusive commercialization agreement with EVERSANA
7M ago
CTOR
CTXR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >